JP2023525495A5 - - Google Patents

Info

Publication number
JP2023525495A5
JP2023525495A5 JP2022566042A JP2022566042A JP2023525495A5 JP 2023525495 A5 JP2023525495 A5 JP 2023525495A5 JP 2022566042 A JP2022566042 A JP 2022566042A JP 2022566042 A JP2022566042 A JP 2022566042A JP 2023525495 A5 JP2023525495 A5 JP 2023525495A5
Authority
JP
Japan
Prior art keywords
containing seq
chain variable
variable domain
sequence
sequence number
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022566042A
Other languages
English (en)
Japanese (ja)
Other versions
JP7734693B2 (ja
JP2023525495A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/029920 external-priority patent/WO2021222587A1/en
Publication of JP2023525495A publication Critical patent/JP2023525495A/ja
Publication of JP2023525495A5 publication Critical patent/JP2023525495A5/ja
Application granted granted Critical
Publication of JP7734693B2 publication Critical patent/JP7734693B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022566042A 2020-04-29 2021-04-29 抗cd26タンパク質及びそれらの使用法 Active JP7734693B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063017467P 2020-04-29 2020-04-29
US63/017,467 2020-04-29
PCT/US2021/029920 WO2021222587A1 (en) 2020-04-29 2021-04-29 Anti-cd26 proteins and uses thereof

Publications (3)

Publication Number Publication Date
JP2023525495A JP2023525495A (ja) 2023-06-16
JP2023525495A5 true JP2023525495A5 (OSRAM) 2024-05-09
JP7734693B2 JP7734693B2 (ja) 2025-09-05

Family

ID=76035139

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022566042A Active JP7734693B2 (ja) 2020-04-29 2021-04-29 抗cd26タンパク質及びそれらの使用法

Country Status (7)

Country Link
US (1) US12497462B2 (OSRAM)
EP (1) EP4143231A1 (OSRAM)
JP (1) JP7734693B2 (OSRAM)
CN (1) CN115836087A (OSRAM)
AU (1) AU2021262794A1 (OSRAM)
CA (1) CA3181417A1 (OSRAM)
WO (1) WO2021222587A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7397874B2 (ja) 2018-08-30 2023-12-13 エイチシーダブリュー バイオロジックス インコーポレイテッド 多鎖キメラポリペプチドおよびその使用
CN120535649A (zh) 2018-08-30 2025-08-26 免疫生物公司 单链嵌合多肽和其用途
WO2020257639A1 (en) 2019-06-21 2020-12-24 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
US12187763B2 (en) 2020-02-11 2025-01-07 Immunitybio, Inc. Chromatography resin and uses thereof
CA3169231A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of treating age-related and inflammatory diseases
AU2021220196A1 (en) 2020-02-11 2022-08-04 HCW Biologics, Inc. Methods of activating regulatory T cells
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
CN119384289A (zh) 2022-04-13 2025-01-28 免疫生物公司 用于治疗神经炎症性障碍的多链嵌合多肽
EP4526681A4 (en) * 2022-05-20 2026-04-01 Academia Sinica Recombinant antibodies, kits containing them, and their uses in the diagnosis of African swine fever virus
CN121109359A (zh) * 2024-11-20 2025-12-12 华中科技大学同济医学院附属协和医院 一种靶向降解蛋白及其应用

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
GB9324807D0 (en) 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
EP0771216B9 (en) 1994-07-11 2003-01-02 The Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of tumoral vasculature
US6117980A (en) 1997-02-21 2000-09-12 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US20060235209A9 (en) 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
US20030109680A1 (en) 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
JP2001206899A (ja) 1999-11-18 2001-07-31 Japan Tobacco Inc TGF−βII型受容体に対するヒトモノクローナル抗体及びその医薬用途
US20010044427A1 (en) 1999-12-20 2001-11-22 Sidney Mazel Pharmaceutical kit
PT1257297E (pt) 2000-02-24 2006-12-29 Philogen Spa Composições e método para tratamento da angiogénese em lesões patológicas
AU2001259215A1 (en) 2000-04-28 2001-11-12 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン,エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
ES2353273T3 (es) 2000-12-26 2011-02-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anticuerpos anti-cd28.
US20040204481A1 (en) 2001-04-12 2004-10-14 Pnina Fishman Activation of natural killer cells by adenosine A3 receptor agonists
WO2002092127A1 (en) * 2001-05-11 2002-11-21 Board Of Regents, The University Of Texas System Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26
WO2003015697A2 (en) 2001-08-13 2003-02-27 University Of Southern California Interleukin-2 mutants with reduced toxicity
TWI338009B (en) 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
WO2003104425A2 (en) 2002-06-07 2003-12-18 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Novel stable anti-cd22 antibodies
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US7572442B2 (en) 2002-07-15 2009-08-11 Board Of Regents, The University Of Texas System Selected antibody compositions for binding to aminophospholipids
AU2003261787B2 (en) 2002-08-30 2008-11-06 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human antihuman interleukin-6 antibody and fragment of the antibody
ES2559763T3 (es) 2002-09-10 2016-02-15 Affimed Gmbh Anticuerpo humano específico de CD3 con propiedades inmunosupresoras
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
WO2004072286A1 (ja) 2003-01-23 2004-08-26 Ono Pharmaceutical Co., Ltd. ヒトpd−1に対し特異性を有する物質
EP1599502A1 (en) 2003-02-27 2005-11-30 TheraVision GmbH A molecule which binds cd80 and cd86
AU2004224277A1 (en) 2003-03-21 2004-10-07 Wyeth Treating immunological disorder using agonists of interleukin-21/ interleukin-21 receptor
AU2004244626A1 (en) 2003-05-23 2004-12-09 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
US9005613B2 (en) 2003-06-16 2015-04-14 Immunomedics, Inc. Anti-mucin antibodies for early detection and treatment of pancreatic cancer
JP2005124568A (ja) 2003-10-01 2005-05-19 Junichi Masuyama 細胞活性化方法及びこれを用いる細胞製造方法並びに医薬組成物
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
JP4939397B2 (ja) 2004-03-30 2012-05-23 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュ ユニバーシティ オブ エルサレム アレルギー性反応に関与する細胞を標的化するための二重特異性抗体、ならびにその組成物および使用
CN101163502A (zh) 2005-02-08 2008-04-16 根茨美公司 针对TGFβ的抗体
US7393833B2 (en) 2005-03-09 2008-07-01 The Board Of Regents Of The University Of Oklahoma Chimeric proteins with phosphatidylserine binding domains
WO2006097743A2 (en) 2005-03-17 2006-09-21 Ucl Biomedica Plc Method for actvating natural killer cells by tumor cell preparation in vitro
CN100509849C (zh) 2005-04-07 2009-07-08 苏州大学 可溶性人cd28分子检测试剂盒及其应用
EP1871418B1 (en) 2005-04-19 2014-03-19 Seattle Genetics, Inc. Humanized anti-cd70 binding agents and uses thereof
NZ562234A (en) 2005-04-26 2009-09-25 Pfizer P-cadherin antibodies
KR101281208B1 (ko) 2005-05-11 2013-07-26 필로겐 에스.피.에이. 피브로넥틴 ed-b에 대한 항체 l19 및 인터루킨12의 융합 단백질
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
ES2456296T3 (es) 2008-03-27 2014-04-21 Zymogenetics, Inc. Composiciones y procedimientos para inhibir PDGFR beta y VEGF-A
HRP20241467T1 (hr) 2008-06-25 2025-01-03 Novartis Ag Stabilna i topljiva protutijela koja inhibiraju vegf
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
US9273136B2 (en) 2008-08-04 2016-03-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human anti-human NKG2D monoclonal antibodies
US8298533B2 (en) 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
EP4209510B1 (en) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
AR078254A1 (es) 2009-09-01 2011-10-26 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
DE102009045006A1 (de) 2009-09-25 2011-04-14 Technische Universität Dresden Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen
MX2012004415A (es) 2009-10-15 2012-05-08 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
BR112012020101A2 (pt) 2010-02-11 2018-09-25 Alexion Pharma Inc método diagnósticos e terapêuticos usando anticorpos anti-cd200.
US9028830B2 (en) 2010-04-08 2015-05-12 JN Biosciences, LLC Antibodies to CD122
WO2011155607A1 (ja) 2010-06-11 2011-12-15 協和発酵キリン株式会社 抗tim-3抗体
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
JP2012034668A (ja) 2010-08-12 2012-02-23 Tohoku Univ ヒト型化抗egfr抗体リジン置換可変領域断片及びその利用
EP2619229B1 (en) 2010-09-21 2016-04-06 Altor BioScience Corporation Multimeric il-15 soluble fusion molecules and methods of making and using same
SG10201508401TA (en) 2010-10-11 2015-11-27 Abbvie Bahamas Ltd Processes for purification of proteins
CN102153653B (zh) 2010-12-30 2012-08-15 厦门大学 肿瘤血管靶向多肽与组织因子的融合蛋白及其制备方法
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
BR112013027021A2 (pt) 2011-04-19 2016-11-29 Merrimack Pharmaceuticals Inc anticorpos anti-igf-1r e anti-erbb3 monoespecíficos e biespecíficos
KR102030987B1 (ko) 2011-04-25 2019-11-11 다이이찌 산쿄 가부시키가이샤 항 b7-h3항체
ES2765874T3 (es) 2011-05-25 2020-06-11 Innate Pharma Sa Anticuerpos anti-KIR para el tratamiento de trastornos inflamatorios
US8753640B2 (en) 2011-05-31 2014-06-17 University Of Washington Through Its Center For Commercialization MIC-binding antibodies and methods of use thereof
PH12013502489B1 (en) 2011-06-03 2019-04-24 Xoma Technology Ltd Antibodies specific for tgf-beta
WO2012170470A1 (en) 2011-06-06 2012-12-13 Board Of Regents Of The University Of Nebraska Compositions and methods for detection and treatment of cancer
US9409988B2 (en) 2011-06-22 2016-08-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-Axl antibodies and uses thereof
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
US8871908B2 (en) 2011-11-11 2014-10-28 Rinat Neuroscience Corp. Antibodies specific for Trop-2 and their uses
SG11201404243WA (en) 2012-01-26 2014-08-28 Nugen Technologies Inc Compositions and methods for targeted nucleic acid sequence enrichment and high efficiency library generation
WO2013134665A1 (en) 2012-03-08 2013-09-12 Selig Sealing Products, Inc. Container sealing member with protected security component and removal tab
KR101535341B1 (ko) 2012-07-02 2015-07-13 한화케미칼 주식회사 Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도
BR112015002085A2 (pt) 2012-08-08 2017-12-19 Roche Glycart Ag proteína, polinucleotídeo, vetor, célula hospedeira, método para produzir a proteína, composição farmacêutica, uso da proteína, método de tratamento e invenção
WO2014026054A2 (en) 2012-08-10 2014-02-13 University Of Southern California CD20 scFv-ELPs METHODS AND THERAPEUTICS
WO2014028560A2 (en) 2012-08-14 2014-02-20 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
CA2879494A1 (en) 2012-08-28 2014-03-06 Institut Curie Cluster of differentiation 36 (cd36) as a therapeutic target for hiv infection
HRP20170743T1 (hr) 2012-11-20 2017-07-28 Sanofi Anti-ceacam5 protutijela i njihova uporaba
EP4001307A1 (en) 2012-12-17 2022-05-25 Cell Medica Inc. Antibodies against il-1 beta
US20140242077A1 (en) 2013-01-23 2014-08-28 Abbvie, Inc. Methods and compositions for modulating an immune response
US9573988B2 (en) 2013-02-20 2017-02-21 Novartis Ag Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
US9790274B2 (en) 2013-03-14 2017-10-17 The Board Of Regents Of The University Of Texas System Monoclonal antibodies targeting EpCAM for detection of prostate cancer lymph node metastases
WO2014190273A1 (en) 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
JP2015030666A (ja) * 2013-07-31 2015-02-16 学校法人順天堂 抗ヒトcd26モノクローナル抗体又はその抗原結合性断片
JP2015054824A (ja) * 2013-09-10 2015-03-23 学校法人順天堂 Mersコロナウイルス感染症予防治療剤
CN103709251B (zh) * 2013-12-19 2016-04-13 江苏众红生物工程创药研究院有限公司 全人源抗cd26抗体及其应用
KR102127408B1 (ko) 2014-01-29 2020-06-29 삼성전자주식회사 항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체
AU2015210750B2 (en) 2014-01-31 2020-08-20 Children's Medical Center Corporation Antibody molecules to TIM-3 and uses thereof
CA2937034A1 (en) 2014-02-03 2015-08-06 Riken Anti-tissue factor monoclonal antibody
FR3021970B1 (fr) 2014-06-06 2018-01-26 Universite Sciences Technologies Lille Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
CR20170060A (es) 2014-08-19 2017-04-18 Merck Sharp & Dohme Anticuerpos anti tigit
CA2951604A1 (en) 2014-08-29 2016-03-03 Pablo Umana Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
EP3789039A1 (en) 2014-12-22 2021-03-10 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
EP3270937A4 (en) 2015-03-26 2018-09-12 The Trustees Of Dartmouth College Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
EP3283523A1 (en) 2015-04-17 2018-02-21 Elsalys Biotech Anti-tyro3 antibodies and uses thereof
KR101778439B1 (ko) 2015-04-27 2017-09-14 울산대학교 산학협력단 자연살해세포 활성화제를 유효성분으로 함유하는 면역증강 및 항암활성증진용 조성물
EP3307772B1 (en) 2015-06-12 2020-09-09 Ludwig Institute For Cancer Research Limited Tgf-beta 3 specific antibodies and methods and uses thereof
ES2710618T3 (es) 2015-08-06 2019-04-26 Agency Science Tech & Res Anticuerpos frente a IL2R-Beta/cadena gamma común
DK3348276T3 (da) * 2015-09-11 2021-08-09 Ys Ac Co Ltd Cancerbehandlingssammensætning, hvor af anti-CD26-antistof og et andet anticancermiddel er kombineret
PH12022553648A1 (en) 2015-09-25 2024-03-11 Genentech Inc Anti-tigit antibodies and methods of use
AU2016353231B2 (en) 2015-11-13 2020-08-13 Dana-Farber Cancer Institute, Inc. An NKG2D-Ig fusion protein for cancer immunotherapy
KR20180107151A (ko) 2016-02-17 2018-10-01 노파르티스 아게 Tgf베타 2 항체
KR20250065434A (ko) 2016-03-01 2025-05-12 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 인간 폴리오바이러스 수용체(pvr)에 특이적인 항체
US11963980B2 (en) 2016-04-25 2024-04-23 Musc Foundation For Research Development Activated CD26-high immune cells and CD26-negative immune cells and uses thereof
KR102650803B1 (ko) 2016-10-05 2024-03-25 유니버시티 오브 센트럴 플로리다 리서치 파운데이션, 인코포레이티드 Nk 세포 및 항-pdl1 암 요법과 관련된 방법 및 조성물
KR102392142B1 (ko) 2016-10-21 2022-04-28 알토 바이오사이언스 코포레이션 다량체 il-15 기반 분자
JP7790686B2 (ja) 2017-01-03 2025-12-23 バイオアトラ インコーポレイテッド 老化細胞の処置のためのタンパク質療法
TWI787230B (zh) 2017-01-20 2022-12-21 法商賽諾菲公司 抗TGF-β抗體及其用途
CA3052886A1 (en) 2017-02-28 2018-09-07 Affimed Gmbh Combination of an anti-cd16a antibody with a cytokine
EP3592778A4 (en) 2017-03-06 2021-01-13 Altor BioScience Corporation IL-15-BASED FUSIONS TO IL-12 AND IL-18
KR20190126182A (ko) 2017-03-27 2019-11-08 난트셀, 인크. aNK 및 IL-12 조성물 및 방법 (ANK AND IL-12 COMPOSITIONS AND METHODS)
EP3421607A1 (en) 2017-06-29 2019-01-02 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Identification and elimination of damaged and/or senescent cells
KR20200090742A (ko) 2017-08-28 2020-07-29 알토 바이오사이언스 엘엘씨 Il-7 및 il-21에의 il-15 기반 융합
CN120535649A (zh) 2018-08-30 2025-08-26 免疫生物公司 单链嵌合多肽和其用途
AU2019328575B2 (en) 2018-08-30 2024-07-11 Immunitybio, Inc. Single-chain and multi-chain chimeric polypeptides and uses thereof
JP7397874B2 (ja) 2018-08-30 2023-12-13 エイチシーダブリュー バイオロジックス インコーポレイテッド 多鎖キメラポリペプチドおよびその使用
WO2020257639A1 (en) 2019-06-21 2020-12-24 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
AU2021220196A1 (en) 2020-02-11 2022-08-04 HCW Biologics, Inc. Methods of activating regulatory T cells
CA3169231A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of treating age-related and inflammatory diseases
US12187763B2 (en) 2020-02-11 2025-01-07 Immunitybio, Inc. Chromatography resin and uses thereof
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
CN119384289A (zh) 2022-04-13 2025-01-28 免疫生物公司 用于治疗神经炎症性障碍的多链嵌合多肽

Similar Documents

Publication Publication Date Title
JP7724332B2 (ja) クローディン18.2結合部分およびその利用
JP7098629B2 (ja) 抗pd-1モノクローナル抗体、その製造方法及び用途
CN102421802B (zh) 人源化的axl抗体
KR101671039B1 (ko) 항 cxcr4 항체 및 그들의 암의 치료를 위한 용도
TW202126692A (zh) 抗人Claudin18.2抗體及其應用
TWI815306B (zh) PD-1/TGF-beta四價雙特異性抗體、其製備方法和用途
CN113906054B (zh) 能够结合cd19和cd3的多特异性抗原结合蛋白及其用途
CN110066336B (zh) 抗cd47单克隆抗体、片段及其医药用途
RU2020120613A (ru) Антитела, нацеленные на рецептор, связанный с g-белками, и способы их применения
WO2013064701A2 (en) Bispecific antibodies and methods for isolating same
JP2023551027A5 (OSRAM)
JP2020521504A (ja) 抗cd40抗体、その抗原結合フラグメント、およびその医学的使用
KR20110010708A (ko) 암을 치료하는데 사용되는 새로운 항체들
JP2024520188A5 (OSRAM)
CN111196854A (zh) Ox40抗体及其制备方法和应用
KR102713140B1 (ko) 항체
CN109721656B (zh) 靶向rankl的治疗性抗体
CN114573702A (zh) 一种新型肿瘤衔接器治疗药物的开发和应用
AU2020400801B2 (en) Anti-BCMA/anti-4-1BB bispecific antibodies and uses thereof
AU2020412201B2 (en) TGF-beta-RII binding proteins
JP2023507277A (ja) 多特異性抗体
CN114573703A (zh) 一种t细胞衔接器治疗剂的开发和应用
IL321677A (en) Anti-PDL1 antibodies, multispecific antibodies, and methods of use
JP2025502379A (ja) Cd25を標的とする抗体及びその製造方法と応用
IL298894A (en) Human anti-grp94 antibodies and uses